Previous 10 | Next 10 |
home / stock / tsha / tsha articles
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during T...
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early c...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Sportradar Group AG (NASDAQ: SRAD) rose sharply durin...
Tuesday, Taysha Gene Therapies Inc (NASDAQ:TSHA) shared initial clinical data from the first pediatric patient from the REVEAL Phase 1/2 ...
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year ...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares are climbing after the company reported its fiscal year 2023 results after the bell Tuesday. Here&...
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage gene therapy comp...
The Dow Jones closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around th...
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
Taysha Gene Therapies Inc. Website:
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for TSHA on June 26, 2024 04:10PM ET. TSHA was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 1 - Hol...
DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an ...
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commen...